French biotech company Innate Pharma has formed a clinical trial collaboration with AstraZeneca’s research and development arm MedImmune to combine their immunotherapies in the Phase I/II STELLAR-001 clinical trial to treat patients suffering from certain solid tumours.

MedImmune’s durvalumab is an anti-PD-L1 immune checkpoint inhibitor, while Innate’s IPH5401 is an investigational anti-C5aR monoclonal antibody.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Both these cancer immunotherapies leverage immune system of the body to fight against cancer.

Durvalumab is designed to counter the immune-evading capability of a tumour by inhibiting PD-L1 interactions with PD-1 and CD80.

In preclinical studies, C5aR blockade was found to enhance immune-mediated destruction of tumours, as well as the efficacy of checkpoint inhibitors.

“We believe IPH5401 could become an important partner in PD-1/PD-L1 combination strategies.”

Phase I of the new trial is set to determine a recommended dose regimen of IPH5401 when given in conjunction with durvalumab, and Phase II portion will investigate the safety and efficacy of this combination therapy.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Under the non-exclusive agreement between, Innate will perform the trial and costs will be equally shared between the company and MedImmune.

Innate Pharma chief executive officer Mondher Mahjoubi said: “Our collaboration with MedImmune provides further evidence of Innate’s commitment to exploring the full combination potential of IPH5401 as we progress our immuno-oncology portfolio.

“We believe IPH5401 could become an important partner in PD-1/PD-L1 combination strategies.”

The firm is currently under a co-development and commercialisation agreement with AstraZeneca for humanised IgG4, monalizumab, being developed to target NKG2A receptors that are expressed on tumour infiltrating cytotoxic NK and CD8 T lymphocytes.